Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
28
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-27 Otsuka Holdings Co.,Ltd. “SIMTRIYO® (centanafazine), a drug with a novel mechanism of action, has received marketing approval in the United States as a treatment for attention-deficit hyperactivity disorder (ADHD).”
28
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-27 Otsuka Holdings Co.,Ltd. “"Pocari Sweat Ion Water Powder Stick Type for 500ml" is now on sale. It supports hydration and electrolyte replenishment in all everyday situations, such as with your own water bottle.”
28
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-27 Otsuka Holdings Co.,Ltd. “Otsuka to Present Pivotal Two-Year eGFR Results from the Phase 3 VISIONARY Trial of VOYXACT (sibeprenlimab-szsi) in IgA Nephropathy (IgAN) at GlomCon Hawaii 2026 (Link to Otsuka America Pharmaceutical's English page).”
28
Jul
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-07-27 DAIICHI SANKYO COMPANY,LIMITED “The European Medicines Agency's recommendation for approval of trastuzumab deruxtecan (T-DXd/DS-8201) and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer (260KB) will open in a new window as a PDF file.”
28
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-27 Eisai Co.,Ltd. “Pfizer and Eisai have begun co-promoting Nartique®, a drug for the prevention (suppression) and treatment of migraines.”
25
Jul
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-07-24 CHUGAI PHARMACEUTICAL CO.,LTD. “Consolidated financial results for the second quarter of the fiscal year ending December 2026.”
25
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-24 Shionogi & Co.,Ltd. “The efficacy of baloxavir and resistance-related mutations against highly pathogenic avian influenza A(H7N9) were evaluated.”
24
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-23 Otsuka Holdings Co.,Ltd. “Notice regarding price revisions for some products.”
24
Jul
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-07-23 CHUGAI PHARMACEUTICAL CO.,LTD. “Regarding F. Hoffmann-La Roche's announcement of its interim financial results for 2026.”
24
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-23 Shionogi & Co.,Ltd. “Regarding the completion of payment for the disposal of treasury stock as restricted stock compensation.”
24
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-23 Shionogi & Co.,Ltd. “Regarding Torii Pharmaceutical's announcement concerning the transfer of manufacturing and marketing approval for the topical corticosteroid preparations "Locoid® Ointment 0.1%" and "Locoid® Cream 0.1%".”
16
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-15 Otsuka Holdings Co.,Ltd. “Announcement of the new domestic launch of the PI3Kα inhibitor "Heitzexin® Tablets 10mg".”
16
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-15 Otsuka Holdings Co.,Ltd. “Otsuka Group to introduce its first battery storage system in the Hokkaido area – aiming to maximize renewable energy use and stabilize power supply, thereby promoting both business growth and environmental responsibility.”
16
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-15 Eisai Co.,Ltd. “The results of the "Rekenbi®" real-world clinical LEADER study were presented at AAIC 2026—among patients with early-stage Alzheimer's disease who received treatment for an average of 17 months, over 75% maintained their disease stage and approximately 7% showed improvement—these real-world clinical data support the long-term benefits of continued administration of "Rekenbi" and provide important insights into the actual treatment practices in daily clinical practice.”
16
Jul
Shionogi & Co.,Ltd. JP3347200002
2026-07-15 Shionogi & Co.,Ltd. “Pharmaceutical x Data Science Meetup 2026: Opportunities for those from outside the industry! Lectures and career counseling on cutting-edge AI and data utilization in the pharmaceutical industry.”
16
Jul
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-07-15 Sumitomo Pharma Co.,Ltd. “The creation of the regenerative medicine product "Amshepri" won the "10th Bioindustry Award".”
15
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-14 Otsuka Holdings Co.,Ltd. “Otsuka Holdings has been selected as a constituent stock of the ESG investment index "FTSE4Good Index Series," "FTSE JPX Blossom Japan Index," and "FTSE JPX Blossom Japan Sector Relative Index."”
15
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-14 Eisai Co.,Ltd. “New findings on Etalanetug (E2814) will be presented at AAIC 2026 – Etalanetug reduces eMTBR-tau243, a blood biomarker specific to tau aggregates in Alzheimer's disease – Measuring the blood biomarker eMTBR-tau243 may be a practical and minimally invasive method for capturing pathological changes specific to Alzheimer's disease, and is expected to play an important role in the future clinical development of etalanetug.”
15
Jul
Eisai Co.,Ltd. JP3160400002
2026-07-14 Eisai Co.,Ltd. “LEQEMBI IQLIK®, a subcutaneous injection formulation of the anti-Aβ antibody LEQEMBI®, has received approval from the U.S. FDA as an initial treatment for early-stage Alzheimer's disease. LEQEMBI IQLIK is the world's first and only anti-amyloid therapy that offers the convenience of home administration from initial treatment to maintenance therapy. LEQEMBI IQLIK is scheduled to be launched in the U.S. in late August 2026 as an initial treatment.”
14
Jul
Otsuka Holdings Co.,Ltd. JP3188220002
2026-07-13 Otsuka Holdings Co.,Ltd. “Notice of price revisions for some products – effective for deliveries from September 1st, 2026 (Tuesday).”